Keywords
immune microthrombovasculitis, treatment, L-arginine, clopedogrel, clinical efficacy
Abstract
Among all the diseases that occur among the world's population, immune microthrombovasculitis (hemorrhagic vasculitis, Shenlein Genox disease) is increasing day by day. In this regard, serum endothelial 1 (ET-1), thrombomodulin, Willebrand factor, and soluble intercellular adhesion factor (sICAM-1) about hemostasis were determined by the shape, severity, duration of disease, and treatment with nitric oxide inducer and angiotensin. Particular attention is paid to increasing the effectiveness of treatment procedures using inhibitory enzyme inhibitors.